enVVeno Medical Corp Files Definitive Proxy Statement

TL;DR

enVVeno Medical Corp filed its DEF 14A proxy statement. Standard stuff for shareholders.

AI Summary

enVVeno Medical Corp (formerly Hancock Jaffe Laboratories, Inc.) filed a Definitive Proxy Statement (DEF 14A) on November 19, 2024, for its fiscal year ending December 31, 2024. The company, located at 70 Doppler, Irvine, CA, operates in the Surgical & Medical Instruments & Apparatus industry. This filing is a standard procedural document related to shareholder matters.

Why It Matters

This filing provides shareholders with essential information regarding company governance and upcoming shareholder meetings, impacting their voting rights and understanding of corporate decisions.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement and does not contain new financial information or strategic changes that would inherently increase risk.

Key Numbers

• 20241218 — Fiscal Year End (Reporting period for the proxy statement.)
• 20241119 — Filing Date (Date the definitive proxy statement was filed with the SEC.)

Key Players & Entities

• enVVeno Medical Corp (company) — Registrant
• Hancock Jaffe Laboratories, Inc. (company) — Former Company Name
• 70 DOPPLER (location) — Business Address
• IRVINE (location) — City
• CA (location) — State
• 92618 (location) — ZIP Code

FAQ

Key Financial Figures

• $48.4 million — We ended the third quarter of 2024 with $48.4 million of cash and investments, which should b
• $0.00001 — d shares of our common stock, par value $0.00001 per share (the " Common Stock " and suc

Filing Documents

• ny20034132x1_def14a.htm (DEF 14A) — 669KB
• ny20034132x1_barchart01x2.jpg (GRAPHIC) — 156KB
• ny20034132x1_barchart02x2.jpg (GRAPHIC) — 163KB
• ny20034132x1_ceoletter.jpg (GRAPHIC) — 29KB
• ny20034132x1_ceoletterhead.jpg (GRAPHIC) — 39KB
• ny20034132x1_pc01.jpg (GRAPHIC) — 720KB
• ny20034132x1_pc02.jpg (GRAPHIC) — 537KB
• 0001140361-24-047305.txt ( ) — 2933KB

Executive Compensation

Executive Compensation 15 Employment Agreements 15 Potential Payments Upon Termination or Change-in-Control 19 Outstanding Equity Awards at Fiscal Year-End 19 Employee Benefit Plans 23 Limitation of Liability and Indemnification Matters 25 Director Compensation 27 Audit Committee Report 28 PROPOSAL 2. APPROVAL, ON A NON-BINDING, ADVISORY BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS 29 PROPOSAL 3. APPROVAL, ON A NON-BINDING, ADVISORY BASIS OF THE FREQUENCY OF CONDUCTING FUTURE STOCKHOLDER ADVISORY VOTES ON NAMED EXECUTIVE OFFICER COMPENSATION 30 PROPOSAL 4. RATIFICATION OF THE APPOINTMENT OF THE COMPANY'S REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL YEAR 2024 31 OTHER INFORMATION 33 Proxy Solicitation 33 Proxies 33 Other Business 33

Legal Proceedings

Legal Proceedings 33 Future Stockholder Proposals 33 Stockholder Communications 33 Householding of Proxy Materials 34 Additional Information 34 i TABLE OF CONTENTS enVVeno Medical Corporation 70 Doppler Irvine, California 92618 (949) 261-2900 PROXY STATEMENT ANNUAL MEETING OF STOCKHOLDERS to be held via live webcast on Wednesday December 18, 2024, 9:00 a.m., Pacific Time QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS Why am I receiving this Proxy Statement? This Proxy Statement describes the proposals on which our Board of Directors (the " Board ") would like you, as a stockholder, to vote on at our 2024 Annual Meeting of the Stockholders (the " Meeting "), which will take place on Wednesday, December 18, 2024 at 9:00 am Pacific time via live webcast. This Proxy Statement also gives you information on these proposals so that you can make an informed decision. We intend to mail this Proxy Statement and accompanying proxy card on or about November 19, 2024, to all stockholders of record entitled to vote at the Meeting. In this Proxy Statement, we refer to enVVeno Medical Corporation as the "Company," "we," "us" or "our" or similar terminology. Who can vote at the Meeting? Stockholders who owned shares of our common stock, par value $0.00001 per share (the " Common Stock " and such shares of held on the Record Date, the " Voting Stock ") on October 21, 2024 (the " Record Date ") may attend and vote at the Meeting. Each share of Common Stock is entitled to one vote. There were 17,535,948 shares of Common Stock outstanding on the Record Date. All shares of Voting Stock vote together as a single class. Shares of the Voting Stock represented by executed proxies received by the Company will be counted for purposes of establishing a quorum at the Meeting, regardless of how or whether such shares are voted on any specific proposal. Information about the stockholdings of our directors and executive officers is contained in the section of

View Full Filing

View this DEF 14A filing on SEC EDGAR